Stanford Reward Circuits of the Brain Study – MDMA

This study is a biomarker study designed to characterize how MDMA impacts the reward circuits of the human brain.

Topic Healthy Subjects PTSD
Compound MDMA
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Stanford University
Researchers at Stanford are exploring the potential of ketamine, MDMA and psilocybin by connecting neuroscience, psychiatry and anesthesiology.

National Institute on Drug Abuse
This company doesn't have a full profile yet, it is linked to a clinical trial.

Papers

Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial
This randomised, double-blind, placebo-controlled clinical trial (n=16) examines MDMA's (80-120mg) effects on neural circuits in individuals with subthreshold PTSD symptoms and early life trauma. The study finds that participants with higher baseline amygdala reactivity (emotional experiences) showed significant reductions in amygdala and sgACC (emotional processing) activity, increased sgACC-amygdala connectivity, and increased likability of threat expressions after 120mg MDMA compared to those with lower baseline reactivity.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.